The COVID-19 Vaccines: Recent Development, Challenges and Prospects
Name
vaccines-09-00349-v2.pdf
Size
599.94 KB
Format
Adobe PDF
Checksum (MD5)
9d36f0efa29894f9c87101bd26092d42
Author(s)
Yan, Yuxin
Pang, Yoongxin
Lyu, Zhuoyi
Wang, Ruiqi
Wu, Xinyun
You, Chong
Zhao, Haitao
Manickam, Sivakumar
Lester, Edward
Wu, Tao
Date Issued
April 2021
Journal
Vaccines
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Yan, Yuxin et al. "The COVID-19 Vaccines: Recent Development, Challenges and Prospects." Vaccines 9, 4 (April 2021): 349 © 2021 The Authors
Version
Final published version
Abstract
The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public.
MIT Department
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/vaccines9040349
